Encouraging results of oral HAE treatment study
From its Phase 1 multiple-ascending-dose study demonstrating PHA121’s pharmacokinetics and tolerability Pharvaris announces that PHA121 was well tolerated at all doses studied, with approximately dose-proportional exposure. “We are encouraged by these results to continue development of PHA121 as an oral treatment for HAE,” says Berndt Modig, CEO and co-founder of Pharvaris. “In 2021, we will [...]